(Q33810882)

29 July 2017

1 reference

title

Psoriasis: current perspectives with an emphasis on treatment (English)

1 reference

29 July 2017

Linden KG

1

1 reference

PubMed ID

10625029

29 July 2017

Weinstein GD

series ordinal

2

1 reference

PubMed ID

10625029

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

American Journal of Medicine

29 July 2017

1 reference

29 July 2017

107

1 reference

29 July 2017

6

1 reference

29 July 2017

595-605

1 reference

29 July 2017

Treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Future psoriasis therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Neuropathogenesis and neuropharmacology of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

The effect of severe psoriasis on the quality of life of 369 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Effects of psychologic intervention on psoriasis: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

The economic impact of psoriasis increases with psoriasis severity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

The annual cost of psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Tonsillitis and chronic psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Problem sites: scalp, palm and sole, and nail.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Aetiology and pathogenesis of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Cell kinetic basis for pathophysiology of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Guidelines of care for psoriasis. Committee on Guidelines of Care. Task Force on Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

7 January 2021

Topical corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Structure-activity relationships of topically active steroids: the selection of fluticasone propionate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Vitamin D analogues and psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Use of budesonide Turbuhaler® in young children suspected of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Recent advances in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Components of the Goeckerman Regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Methotrexate and other chemotherapeutic agents used to treat psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Methotrexate in psoriasis: consensus conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Systemic retinoids for psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Oral retinoids--efficacy and toxicity in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

The retinoids. A review of their clinical pharmacology and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

The safety of etretinate as long-term therapy for psoriasis: Results of the Etretinate Follow-up Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Adverse reactions to oral retinoids. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Long-term safety of cyclosporine in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

Cyclosporine as maintenance therapy in patients with severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

An approach to the treatment of moderate to severe psoriasis with rotational therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

The human pharmacology of fluticasone propionate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900284-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)00284-3

1 reference

29 July 2017

1 reference

PubMed ID

10625029